Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Strongyle Infections, Equine D013319 1 associated lipids
Basal Ganglia Hemorrhage D020145 1 associated lipids
Osteoblastoma D018215 1 associated lipids
Edema, Cardiac D004489 1 associated lipids
Radiculopathy D011843 1 associated lipids
Erythromelalgia D004916 1 associated lipids
Oligomenorrhea D009839 1 associated lipids
Intracranial Hemorrhage, Hypertensive D020299 1 associated lipids
Cholecystitis, Acute D041881 1 associated lipids
Atrial Premature Complexes D018880 1 associated lipids
Bluetongue D001819 1 associated lipids
Gastric Dilatation D013271 1 associated lipids
Latex Hypersensitivity D020315 1 associated lipids
Stomach Volvulus D013277 1 associated lipids
Foot Rot D005535 1 associated lipids
Frostbite D005627 1 associated lipids
Tachycardia, Paroxysmal D013614 2 associated lipids
Mixed Connective Tissue Disease D008947 2 associated lipids
Fibromuscular Dysplasia D005352 2 associated lipids
Heart Septal Defects D006343 2 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Schorer AE Discordant effects on eicosanoids and fibrin degradation products in two murine models of antiphospholipid antibody. 1997 Thromb. Res. pmid:9062953
Kosaki G et al. The mechanism of the inhibitory effect of protease inhibitors on platelet aggregation and cellular synthesis of prostaglandins. I. The effect on the release of arachidonic acid from phospholipids. 1980 Dec 1-15 Thromb. Res. pmid:6785893
Anfossi G et al. Studies on in vitro effect of picotamide on human platelet aggregation in platelet-rich plasma and whole blood. 1995 Thromb. Res. pmid:7778055
Watanabe T et al. Enhanced platelet sensitivity to prostacyclin in patients in an active stage of Takayasu arteritis. 2001 Thromb. Res. pmid:11672751
Carroll RC et al. Post interventional cardiology urinary thromboxane correlates with PlateletMapping detected aspirin resistance. 2010 Thromb. Res. pmid:19962724
Lee GY et al. Antiplatelet activity of BRX-018, (6aS,cis)-malonic acid 3-acetoxy-6a9-bis-(2-methoxycarbonyl-acetoxy)-6,6a,7,11b-tetrahydro-indeno[2,1-c]chromen-10-yl ester methylester. 2005 Thromb. Res. pmid:15668191
Ziegler BK et al. Incomplete thromboxane inhibition with 100 mg of intravenous acetylsalicylic acid in patients with acute ST elevation myocardial infarction: a placebo-controlled pilot trial. 2001 Thromb. Res. pmid:11672759
Boyd JA and Eling TE Prostaglandin release and the interaction of platelets with the pulmonary vasculature of rat and guinea pig. 1980 Jul 1-15 Thromb. Res. pmid:7003800
Ersöz G et al. The effect of submaximal exercise on platelet aggregation during late follicular and midluteal phases in women. 2002 Thromb. Res. pmid:12590951
Martin JF et al. Effect of acetylsalicylic acid on platelet aggregation and thromboxane B2 production in flowing aortic blood in the rat studied with a filter loop technique. 1982 Thromb. Res. pmid:6814004
Kawamura M et al. Evaluation of plasma 11-dehydro-thromboxane B2 as an indicator for thromboxane A2 synthesis in vivo in laboratory animals. 1995 Thromb. Res. pmid:7778061
Ersöz G et al. Effect of sodium selenite treatment on platelet aggregation of streptozotocin-induced diabetic rats. 2003 Thromb. Res. pmid:14698654
Teng CM et al. Two antiplatelet agents from Magnolia officinalis. 1988 Thromb. Res. pmid:3413728
Addonizio VP et al. Inhibition of human platelet function by verapamil. 1982 Thromb. Res. pmid:7164035
Vargaftig BB et al. Adrenaline and PAF-acether synergize to trigger cyclooxygenase-independent activation of plasma-free human platelets. 1982 Thromb. Res. pmid:7164036
Vlodavsky I et al. Platelet interaction with the extracellular matrix produced by cultured endothelial cells: a model to study the thrombogenicity of isolated subendothelial basal lamina. 1982 Thromb. Res. pmid:7179215
Saldeen P et al. Thromboxane production in umbilical vein grafts. 1984 Thromb. Res. pmid:6546814
Udvardy M et al. Plasma thromboxane and prostacyclin metabolite ratio in atherosclerosis and diabetes mellitus. 1987 Thromb. Res. pmid:3116717
Cholette JM et al. Aspirin resistance following pediatric cardiac surgery. 2010 Thromb. Res. pmid:20550971
Umemura K et al. Effect of dietary docosahexaenoic acid in the rat middle cerebral artery thrombosis model. 1995 Thromb. Res. pmid:7660354
García Frade LJ et al. Diabetes mellitus as a hypercoagulable state: its relationship with fibrin fragments and vascular damage. 1987 Thromb. Res. pmid:3118498
Carter AJ et al. Human pulmonary vessels obtained from necropsy produce less prostacyclin and thromboxane than fresh vessels obtained from operations. 1984 Thromb. Res. pmid:6547546
Cerskus AL et al. Effects of indomethacin and sulfinpyrazone on in vivo formation of thromboxane B2 and prostaglandin D2 during arachidonate infusion in rabbits. 1978 Thromb. Res. pmid:653641
Rousson D et al. Acute myocardial infarction: measurement of arachidonate end-products in whole blood as an index of platelet cyclo-oxygenase activity in vivo. 1987 Thromb. Res. pmid:3122356
Hanasaki K and Arita H Characterization of a new compound, S-145, as a specific TXA2 receptor antagonist in platelets. 1988 Thromb. Res. pmid:2839912
Ditter H et al. Effects of prostacyclin during cardiopulmonary bypass in men on plasma levels of beta-thromboglobulin, platelet factor 4, thromboxane B2, 6-keto-prostaglandin F1 alpha and heparin. 1983 Thromb. Res. pmid:6197766
Navran SS et al. Human platelet activation by bacterial phospholipase C is mediated by phosphatidylinositol hydrolysis but not generation of phosphatidic acid: inhibition by a selective inhibitor of phospholipase C. 1984 Thromb. Res. pmid:6372157
Shorr RI et al. In vitro effects of acetaminophen and its analogues on human platelet aggregation and thromboxane B2 synthesis. 1985 Thromb. Res. pmid:3923647
Cerskus AL et al. Thromboxane B2 and 6-keto-prostaglandin F1 alpha synthesis during infusion of collagen and arachidonic acid in rabbits: inhibition by aspirin and sulfinpyrazone. 1980 Thromb. Res. pmid:7414555
Ishikawa Y et al. Effect of cytoplasmic pH on platelet activation by arachidonic acid. 1989 Thromb. Res. pmid:2499076
Castaldi PA et al. Evidence for a platelet membrane defect in the myeloproliferative syndromes. 1982 Thromb. Res. pmid:6960545
Kankuri E et al. Effects of phenacetin and its metabolite p-phenetidine on COX-1 and COX-2 activities and expression in vitro. 2003 Thromb. Res. pmid:14592552
Lages B and Weiss HJ Inhibition of human platelet function in vitro and ex vivo by acetaminophen. 1989 Thromb. Res. pmid:2499947
Küster LJ et al. Mechanism of PAF-induced platelet aggregation in man. 1986 Thromb. Res. pmid:3764802
Dalli E et al. Effects of hawthorn (Crataegus laevigata) on platelet aggregation in healthy volunteers. 2011 Thromb. Res. pmid:21737127
Reimers HJ et al. Impaired thromboxane synthesis in preactivated human blood platelets: agonist-specific, irreversible desensitization to thrombin. 1987 Thromb. Res. pmid:3126557
Mercer JB et al. The effect of short-term cold exposure on risk factors for cardiovascular disease. 1999 Thromb. Res. pmid:10418798
Perneby C et al. Prothrombotic responses to exercise are little influenced by clopidogrel treatment. 2004 Thromb. Res. pmid:15381386
Hall ER et al. The reduction of platelet thrombi on damaged vessel wall by a thromboxane synthetase inhibitor in rabbits. 1982 Thromb. Res. pmid:6891109
Lukasik M et al. Aspirin treatment influences platelet-related inflammatory biomarkers in healthy individuals but not in acute stroke patients. 2011 Thromb. Res. pmid:21788065
Gerrard JM et al. Studies in patients with bleeding disorders show that platelet-vessel interaction is important for thromboxane formation in bleeding time wounds. 1990 Thromb. Res. pmid:2278038
Ali M et al. Synthesis of prostaglandin D2 and thromboxane B2 by human platelets. 1977 Thromb. Res. pmid:918907
Arruzazabala ML et al. Effects of Policosanol on platelet aggregation in rats. 1993 Thromb. Res. pmid:8475481
Cattaneo M et al. In vitro effects of picotamide on human platelet aggregation, the release reaction and thromboxane B2 production. 1991 Thromb. Res. pmid:1926062
Udvardy M et al. Alterations of primary haemostasis in mixed connective tissue disease (MCTD). 1991 Thromb. Res. pmid:1835548
Patrono C et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. 1980 Feb 1-15 Thromb. Res. pmid:7368167
Lin CH et al. HA-29: an inhibitor of thromboxane A2 formation with antagonism of thromboxane A2/prostaglandin endoperoxide receptor in rabbit platelets. 1992 Thromb. Res. pmid:1412184
Koh H et al. A radioimmunoassay of thromboxane B2 with thromboxane B2-125I-tyramide and its application to the study on the thromboxane B2 formation during platelet aggregation. 1980 Feb 1-15 Thromb. Res. pmid:7368170
Kohda N et al. Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. 1999 Thromb. Res. pmid:10593428
Marasini B et al. Cigarette smoking and platelet function. 1986 Thromb. Res. pmid:3787563
Matsuo T et al. A new thrombin inhibitor MD805 and thrombocytopenia encountered with heparin hemodialysis. 1986 Thromb. Res. pmid:3787568
Deckmyn H et al. Prostacyclin production by whole blood from children: impairment in the hemolytic uremic syndrome and excessive formation in chronic renal failure. 1983 Thromb. Res. pmid:6344317
Nosál' R et al. Chloroquine: a multipotent inhibitor of human platelets in vitro. 2000 Thromb. Res. pmid:10828481
Chakroun T et al. Screening for aspirin resistance in stable coronary artery patients by three different tests. 2007 Thromb. Res. pmid:17553552
Buchanan MR et al. The sex-related differences in aspirin pharmacokinetics in rabbits and man and its relationship to antiplatelet effects. 1983 Thromb. Res. pmid:6221436
Neiman J et al. Composition of platelet phosphatidylinositol and phosphatidylcholine after ethanol withdrawal. 1987 Thromb. Res. pmid:3603426
Randall MJ and Wilding RI Acute arterial thrombosis in rabbits: reduced platelet accumulation after treatment with thromboxane synthetase inhibitor dazoxiben hydrochloride, (UK-37, 248-01). 1982 Thromb. Res. pmid:6897751
Vesterqvist O et al. Development of a GC-MS method for quantitation of 2,3-dinor-TxB2 and determinations of the daily urinary excretion rates in healthy humans. 1984 Thromb. Res. pmid:6695361
Best LC et al. Mode of action of dipyridamole on human platelets. 1979 Thromb. Res. pmid:229583
Zijlstra FJ et al. Thrombotic thrombocytopenic purpura and plasma thromboxane B2 levels. 1983 Thromb. Res. pmid:6684333
Petroni A et al. Inhibition of platelet aggregation and eicosanoid production by phenolic components of olive oil. 1995 Thromb. Res. pmid:7482432
De La Cruz JP et al. Antithrombotic potential of olive oil administration in rabbits with elevated cholesterol. 2000 Thromb. Res. pmid:11113274
Barnhart MI et al. DDAVP: does the drug have a direct effect on the vessel wall? 1983 Thromb. Res. pmid:6415852
Maderna P et al. Differential effects of oral administrations to human volunteers of acetylsalicylic acid, sodium salicylate and indomethacin on 12-hydroxyeicosatetraenoic acid formation by stimulated platelets. 1988 Thromb. Res. pmid:3194896
Todd MK et al. Effect of exercise intensity on 6-keto-PGF1 alpha, TXB2, and 6-keto-PGF1 alpha/TXB2 ratios. 1992 Thromb. Res. pmid:1615492
Dembinska-Kiec A et al. Ticlopidine and platelet function in healthy volunteers. 1992 Thromb. Res. pmid:1615496
Saldeen P and Saldeen T 6-keto-prostaglandin F1 alpha/thromboxane B2 ratio in vascular and lung tissue. 1983 Thromb. Res. pmid:6688484
Teng CM et al. Inhibition of thrombin- and collagen-induced phosphoinositides breakdown in rabbit platelets by a PAF antagonist--denudatin B, an isomer of kadsurenone. 1990 Thromb. Res. pmid:2169076
Platelet function during long-term treatment with ketanserin of claudicating patients with peripheral atherosclerosis. A multi-center, double-blind, placebo-controlled trial. The PACK Trial Group. 1989 Thromb. Res. pmid:2528841
Maguire ED and Wallis RB In vivo redirection of prostaglandin endoperoxides into 6-keto PGF1 alpha formation by thromboxane synthetase inhibitors in the rat. 1983 Thromb. Res. pmid:6689221
Igawa T et al. Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells. 1990 Thromb. Res. pmid:2158154
Yue TL et al. Pharmacological profile of G619, a new platelet aggregation inhibitor. 1992 Thromb. Res. pmid:1412200
Russell NH et al. Platelet adenine nucleotides and arachidonic acid metabolism in the myeloproliferative disorders. 1981 Thromb. Res. pmid:6794179
Di Minno MN et al. Genotype-independent in vivo oxidative stress following a methionine loading test: maximal platelet activation in subjects with early-onset thrombosis. 2011 Thromb. Res. pmid:21669453
Lagarde M et al. Increase of platelet thromboxane A2 formation and of its plasmatic half-life in diabetes mellitus. 1980 Thromb. Res. pmid:7466751
Ames PR et al. Aspirin insensitive thromboxane generation is associated with oxidative stress in type 2 diabetes mellitus. 2012 Thromb. Res. pmid:22521214
Saloheimo P et al. Thromboxane and prostacyclin biosynthesis in patients with acute spontaneous intracerebral hemorrhage. 2005 Thromb. Res. pmid:15733969
Vesterqvist O et al. In vivo production of thromboxane in acute human myocardial infarction: a preliminary study. 1985 Thromb. Res. pmid:3992528
Chiang TM and Kang AH The effect of platelet surface protein phosphorylation on collagen-platelet interaction. 1986 Thromb. Res. pmid:3810565
Hofmann D et al. Evidence for sustained platelet activation in patients with early postinfarction angina. 1993 Thromb. Res. pmid:8303651
Toft G et al. Intravenously and topically applied magnesium in the prevention of arterial thrombosis. 2000 Thromb. Res. pmid:10904104
Knapp HR et al. Effects of low-dose aspirin on endogenous eicosanoid formation in normal and atherosclerotic men. 1988 Thromb. Res. pmid:3293263
Randall MJ et al. UK-37, 248, a novel, selective thromboxane synthetase inhibitor with platelet anti-aggregatory and anti-thrombotic activity. 1981 Jul 1-15 Thromb. Res. pmid:6795753
De Caterina R et al. Inhibition of platelet aggregation and thromboxane B2 production during aspirin treatment: dependence on the dose of the aggregating agent. 1985 Thromb. Res. pmid:3975876
Selley ML et al. The effect of cholesterol oxidation products on human platelet aggregation. 1996 Thromb. Res. pmid:8885139
Kritz H et al. Isradipine increases vascular prostaglandin I2-formation while the thromboxane B2-synthesis is diminished. 1995 Thromb. Res. pmid:8610276
Bergqvist D et al. The effect of inhibition of thromboxane synthesis in experimental thrombosis and hemostasis. 1985 Thromb. Res. pmid:3838828
Domoto DT et al. Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. 1991 Thromb. Res. pmid:1926064
Wang JP et al. XC 386: a new antiplatelet agent. 1984 Thromb. Res. pmid:6438827
Perneby C et al. Optimization of an enzyme immunoassay for 11-dehydro-thromboxane B(2) in urine: comparison with GC-MS. 1999 Thromb. Res. pmid:10632465
Küster LJ and Frölich JC PAF-induced platelet aggregation and TXB2 formation. 1989 Thromb. Res. pmid:2922704
Driss F et al. Inhibition of platelet aggregation and thromboxane synthesis after intake of small amount of icosapentaenoic acid. 1984 Thromb. Res. pmid:6098051
Mogensen F et al. Effect of specific thromboxane-synthetase inhibition on thromboxane and prostaglandin synthesis in stable angina induced by exercise test. 1985 Thromb. Res. pmid:4038824
Tzeng SH et al. Inhibition of platelet aggregation by some flavonoids. 1991 Thromb. Res. pmid:1776142
Antonino MJ et al. Antiplatelet effects of aspirin with phytosterols: comparison with non-enteric coated aspirin alone. 2010 Thromb. Res. pmid:19446864
Altman R et al. Why single daily dose of aspirin may not prevent platelet aggregation. 1988 Thromb. Res. pmid:3140408
Weigel G et al. Regulation of eicosanoid release in human umbilical endothelial cells. 1991 Thromb. Res. pmid:1656543
Ko FN et al. Antiplatelet effects of protopine isolated from Corydalis tubers. 1989 Thromb. Res. pmid:2559491
Swart SS et al. Functional significance of the platelet alpha2-adrenoceptor: studies in patients with myeloproliferative disorders. 1984 Thromb. Res. pmid:6326344
Meyers KM et al. An evaluation of the arachidonate pathway of platelets from companion and food-producing animals, mink, and man. 1980 Thromb. Res. pmid:7209869